Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jan 2010 Actual patient number (35) added as reported by ClinicalTrials.gov.
- 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2008 The expected completion date for this trial has been extended from Aug 2007 to Nov 2009 as reported by ClinicalTrails.gov.